$PRCT

Wood Larry L purchased $498K of PRCT (indirect holdings)

Wood Larry L (President, CEO) purchased 23,900 indirectly-held shares of PROCEPT BioRobotics Corp (PRCT) at $20.85 ($0.50M total) on 2026-08-07.

Original reporting
SEC EDGAR · Wood Larry L
Published Aug 10, 2026, 10:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PRCT
Bullish
medium confidence
Mentioned
$PRCT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRCTBullishLow
01

Why it matters

This provides a new, dated insider purchase detail (23,900 shares at $20.85) but does not include any new clinical, regulatory, financial, or strategic information that would change valuation assumptions.

02

Market read

Traders may view the insider purchase as a modest bullish sentiment input, but it is unlikely to be a standalone driver of price without accompanying fundamentals.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it also does not clarify the source of the indirect position or whether it is part of a broader compensation or trust structure.

Relevance 5/10Novelty 4/10Timing: filed 2026-08-10, transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Procept BioRobotics (PRCT).

Company-level read

Ticker impact

$PRCTBullishMedium confidence
Context

Procept BioRobotics CEO Larry L Wood filed a Form 4 for an indirect open-market purchase of 23,900 shares at $20.85 on 2026-08-07.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat insider buying as bullish.

Evidence & confidence

Form 4s are primary disclosures, but this is an indirect holding and the text provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be driven by diversification, tax planning, or pre-existing arrangements, and indirect holdings may not reflect immediate conviction.

Key entities

  • PROCEPT BioRobotics Corp

    Subject of the Form 4 insider transaction disclosure.

  • Wood Larry L

    President and CEO; reported an indirect open-market purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.